Hepato-splenomegaly

Gastroenterology
0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

C
CENTOGENEGermany - Rostock
1 program
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)N/A1 trial
Active Trials
NCT02298647Withdrawn0Est. Feb 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
CENTOGENEBiomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)

Clinical Trials (1)

NCT02298647CENTOGENEBiomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)

Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)

Start: Aug 2018Est. completion: Feb 20210
N/AWithdrawn

Related Jobs in Gastroenterology

Specialty Representative, Gastroenterology – Minneapolis, Minnesota

AbbVie
Remote
12h ago

Head of Drug Product Development

Ironwood Pharmaceuticals
Boston, Massachusetts, United States
14h ago
$246K - $287K/yr

Regulatory Affairs Associate

Ferring Pharmaceuticals
Istanbul, Turkey
Yesterday

Key Account Director, Diagnostics and Research

Tempus
Remote
Yesterday
$150K - $200K/yr

Senior Sterilization Validation Engineer (m/f/d)

Johnson & Johnson
Beerse, Antwerp, Belgium
Yesterday

Senior Financial Analyst - Supply Chain Finance & Transformation (m/f/d)

Johnson & Johnson
Norderstedt, Schleswig-Holstein, Germany
Yesterday

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space

Related Indications

Hepatic Impairment(79)Gastroesophageal Reflux Disease(37)Irritable Bowel Syndrome(29)Gastroesophageal Reflux(27)Liver Transplantation(24)Celiac Disease(23)Hepatic Insufficiency(22)Liver Cirrhosis(22)Gastroesophageal Reflux Disease (GERD)(14)Hepatic Encephalopathy(12)